Eris Lifesciences Share Price

The pharmaceutical company reported robust growth in domestic formulations and insulin franchise performance, while maintaining a strong EBITDA margin of 37 per cent

• Business Standard
• 1 week 6 days ago

Pharmaceuticals company Eris Lifesciences announced Q4FY26 & FY26 results Consolidated Financial Highlights: Total Revenue from Operations: Q4FY26: Rs 756.56 crore compared to Rs 705.30 crore in Q4FY25 (YoY growth of ~7.3%). FY26: Rs 3,129.42 crore compared to Rs 2,893.64 crore in FY25 (YoY growth of ~8.1%). Net Profit for the period: Q4FY26: Rs 279.10 crore compared to Rs 102.35 crore in Q4FY25 (YoY growth of ~172.7%). FY26: Rs 647.51 crore compared to Rs 374.67 crore in FY25 (YoY growth of ~72.8%). Standalone Financial Highlights: Total Revenue from Operations: Q4FY26: Rs 277.31 crore compared to Rs 404.77 crore in Q4FY25 (YoY decline of ~31.5%). FY26: Rs 1,821.74 crore compared to Rs 1,697.75 crore in FY25 (YoY growth of ~7.3%). Net Profit for the period: Q4FY26: Net loss of Rs 8.60 crore compared to profit of Rs 30.47 crore in Q4FY25. FY26: Rs 244.05 crore compared to Rs 77.39 crore in FY25 (YoY growth of ~215.3%). Business Highlights: Dividend Declaration: The Board declared an interim dividend of Rs 7.21 per fully paid-up equity share (at the rate of 721%) for the financial year 2026-2027. The record date is May 29, 2026, and payment will be made on or before June 19, 2026. Acquisitions: Swiss Parenteral Limited (SPL): Completed the acquisition of the remaining minority shares on January 16, 2026, making it a wholly-owned subsidiary. Branded Probiotics Business: Completed the acquisition from Velbiom Probiotics Private Limited on March 31, 2026, for a consideration of Rs 50 crore on a slump sale basis. Regulatory/Tax Impact: Due to eligibility for the concessional tax regime from the financial year 2026-27, the Company remeasured deferred tax assets and liabilities, resulting in a deferred tax credit of Rs 150 crore (consolidated) and Rs 18 crore (standalone) recognized in the Statement of Profit and Loss. Exceptional Items: The Company recorded an exceptional item charge of Rs 17.24 crore (consolidated) and Rs 14.67 crore (standalone) in FY26 related to an increase in gratuity and leave liability due to the implementation of the New Labour Codes. Scheme of Arrangement: The Board approved a composite scheme of arrangement to vest the "Domestic Business" of Eris Oaknet Healthcare Private Limited (EOHPL) into Eris Therapeutics Limited (ETL) and the amalgamation of Aprica Healthcare Limited (AHL) with ETL. This is subject to necessary statutory approvals. Result PDF

• Trendlyne
• 1 week 6 days ago

Pharmaceuticals company Eris Lifesciences announced Q3FY26 results Revenue from operations: Rs 807.45 crore against Rs 727.45 crore during Q3FY25, change 11%. PBT: Rs 145.35 crore against Rs 116.36 crore during Q3FY25, change 25%. PAT: Rs 108.83 crore against Rs 87.06 crore during Q3FY25, change 25%. EPS: Rs 7.32 for Q3FY26. Q3 Capex Rs 78 crore – largely towards Insulin/ GLP-1 and General Injectables Book Tax Rate – 22.5% in Q3 OCF-to-EBIDTA ratio: 50% in Q3-26 vs 120% in Q3-25 Result PDF

• Trendlyne
• 3 months 2 weeks ago